Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T20:32:56.488Z.
Calculation as of: 2026-10-06T20:32:56.488Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 08fea6a2878daf509c4a2714b7418dcfec0265989d531cb4479ebc608e1bd708
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Sagimet Biosciences Inc.
Market Cap
$285.42M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.55M
Free Cash Flow Yield
N/A
TTM Avg
2.65%
3Y Avg
2.65%
5Y Avg
2.65%
Market Cap
$282.64M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.79M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.54M
Free Cash Flow Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
Market Cap
$280.37M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.59M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$293.30M
Free Cash Flow Yield
N/A
TTM Avg
41.16%
3Y Avg
41.16%
5Y Avg
41.16%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.42M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | N/A | 2.65% | 2.65% | 2.65% |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $282.64M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | N/A | 1.78% | 1.78% | 1.78% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | N/A | 41.16% | 41.16% | 41.16% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A | 11.89% | 9.26% | 7.84% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
